Population longitudinal analysis of Gait Profile Score and North Star Ambulatory Assessment in children with Duchenne muscular dystrophy

被引:0
作者
Deng, Jiexin [1 ]
Liu, Fangli [1 ]
Feng, Zhifen [1 ]
Liu, Zhigang [2 ]
机构
[1] Henan Univ, Sch Nursing & Hlth, Kaifeng, Henan, Peoples R China
[2] Henan Univ, Affiliated Hosp 1, Dept Orthoped, Kaifeng, Henan, Peoples R China
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2024年 / 13卷 / 05期
关键词
LONG-TERM BENEFITS; 6-MINUTE WALK TEST; NATURAL-HISTORY; GLUCOCORTICOIDS; DEFLAZACORT; MANAGEMENT; THERAPY; BOYS; CARDIOMYOPATHY; DIAGNOSIS;
D O I
10.1002/psp4.13126
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Duchenne muscular dystrophy (DMD) is a rare X-linked recessive disorder characterized by loss-of-function mutations in the gene encoding dystrophin. These mutations lead to progressive functional deterioration including muscle weakness, respiratory insufficiency, and musculoskeletal deformities. Three-dimensional gait analysis (3DGA) has been used as a tool to analyze gait pathology through the quantification of altered joint kinematics, kinetics, and muscle activity patterns. Among 3DGA indices, the Gait Profile Score (GPS), has been used as a sensitive overall measure to detect clinically relevant changes in gait patterns in children with DMD. To enhance our understanding of the clinical translation of 3DGA, we report here the development of a population nonlinear mixed-effect model that jointly describes the disease progression of the 3DGA index, GPS, and the functional endpoint, North Star Ambulatory Assessment (NSAA). The final model consists of a quadratic structure for GPS progression and a linear structure for GPS-NSAA correlation. Our model was able to capture the improvement in function in GPS and NSAA in younger subjects, as well as the decline of function in older subjects. Furthermore, the model predicted NSAA (CFB) at 1 year reasonably well for DMD subjects <= 7 years old at baseline. The model tended to slightly underpredict the decline in NSAA after 1 year for those >7 years old at baseline, but the prediction summary statistics were well maintained within the standard deviation of observed data. Quantitative models such as this may help answer clinically relevant questions to facilitate the development of novel therapies in DMD.
引用
收藏
页码:891 / 903
页数:13
相关论文
共 72 条
  • [1] DEFLAZACORT IN DUCHENNE DYSTROPHY - STUDY OF LONG-TERM EFFECT
    ANGELINI, C
    PEGORARO, E
    TURELLA, E
    INTINO, MT
    PINI, A
    COSTA, C
    [J]. MUSCLE & NERVE, 1994, 17 (04) : 386 - 391
  • [2] The role of corticosteroids in muscular dystrophy: A critical appraisal
    Angelini, Corrado
    [J]. MUSCLE & NERVE, 2007, 36 (04) : 424 - 435
  • [3] Angelini Corrado, 2012, Acta Myol, V31, P9
  • [4] Duchenne Muscular Dystrophy The Effect of Glucocorticoids on Ventilator Use and Ambulation
    Bach, John R.
    Martinez, Daniel
    Saulat, Bilal
    [J]. AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION, 2010, 89 (08) : 620 - 624
  • [5] The Gait Profile Score and Movement Analysis Profile
    Baker, Richard
    McGinley, Jennifer L.
    Schwartz, Michael H.
    Beynon, Sarah
    Rozumalski, Adam
    Graham, H. Kerr
    Tirosh, Oren
    [J]. GAIT & POSTURE, 2009, 30 (03) : 265 - 269
  • [6] Correlations of the Gait Profile Score and the Movement Analysis Profile relative to clinical judgments
    Beynon, Sarah
    McGinley, Jennifer L.
    Dobson, Fiona
    Baker, Richard
    [J]. GAIT & POSTURE, 2010, 32 (01) : 129 - 132
  • [7] Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade
    Biggar, WD
    Harris, VA
    Eliasoph, L
    Alman, B
    [J]. NEUROMUSCULAR DISORDERS, 2006, 16 (04) : 249 - 255
  • [8] Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols
    Biggar, WD
    Politano, L
    Harris, VA
    Passamano, L
    Vajsar, J
    Alman, B
    Palladino, A
    Comi, LI
    Nigro, G
    [J]. NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 476 - 482
  • [9] Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
    Birnkrant, David J.
    Bushby, Katharine
    Bann, Carla M.
    Alman, Benjamin A.
    Apkon, Susan D.
    Blackwell, Angela
    Case, Laura E.
    Cripe, Linda
    Hadjiyannakis, Stasia
    Olson, Aaron K.
    Sheehan, Daniel W.
    Bolen, Julie
    Weber, David R.
    Ward, Leanne M.
    [J]. LANCET NEUROLOGY, 2018, 17 (04) : 347 - 361
  • [10] Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
    Birnkrant, David J.
    Bushby, Katharine
    Bann, Carla M.
    Apkon, Susan D.
    Blackwell, Angela
    Colvin, Mary K.
    Cripe, Linda
    Herron, Adrienne R.
    Kennedy, Annie
    Kinnett, Kathi
    Naprawa, James
    Noritz, Garey
    Poysky, James
    Street, Natalie
    Trout, Christina J.
    Weber, David R.
    Ward, Leanne A.
    [J]. LANCET NEUROLOGY, 2018, 17 (05) : 445 - 455